You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
4 November 2024
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
16 October 2024
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
30 September 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
27 September 2024
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
17 September 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
25
Nov 24
Analysts’ Conference
Nov
2024
Press Release – quarterly statement (call-date Q3)
22 October 2024
Half-yearly financial statements 2024
29 April 2024
Annual financial statements 2023
30 August 2023
Half-yearly financial statements 2023
1 October 2024
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
19 August 2024
13 June 2024
21 August 2023
23 September 2022
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Kaufen
7 September 2022
